GB Sciences, Inc. (GBLX)
Chart Events
Performance Outlook
| Previous Close | 0.0270 |
| Open | 0.0250 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0250 - 0.0290 |
| 52 Week Range | 0.0200 - 0.0500 |
| Volume | |
| Avg. Volume | 153,666 |
| Market Cap | 8.496M |
| Beta (5Y Monthly) | 0.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0070 |
| Earnings Date | Aug 28, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Gb Sciences is Leading Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™
As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology. Featured Image for Gb Sciences Featured Image for Gb Sciences LAS VEGAS, July 19, 2022 (GLOBE NEWSWIRE) -- Gb Sciences is a plant-inspired, biopharmaceutical research and drug development company that began building its proprietary digital research and analytics platform long before the pandemic sparked a digital transformation. According to
- GlobeNewswire
Gb Sciences Leads Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™
As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology. Featured Image for Gb Sciences Featured Image for Gb Sciences LAS VEGAS, July 18, 2022 (GLOBE NEWSWIRE) -- Gb Sciences is a plant-inspired, biopharmaceutical research and drug development company that began building its proprietary digital research and analytics platform long before the pandemic sparked a digital transformation. According to
- GlobeNewswire
TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson's Disease at 2022 NeuroForum Summit
Dr. Andrea Small-Howard explains that Gb Sciences' multicomponent Parkinson's disease therapeutic addresses this multi-factorial neurodegenerative condition using a combination of cannabinoids that are more effective when used together than singularly, as demonstrated in an animal model of the disease. Featured Image for Gb Sciences Featured Image for Gb Sciences LAS VEGAS, May 23, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX),
